Psilocybin Shows Significant Benefit in Treatment-Resistant Depression Trial in NHS

Psilocybin-assisted therapy significantly improved depression symptoms in adults with treatment-resistant major depressive disorder, according to a randomized controlled trial published August 6, 2026, in Nature Medicine.

The study, conducted within the National Health Service (NHS) in England, found the treatment was well-tolerated. Because the trial was publicly funded, the results support the feasibility of integrating such therapies into public healthcare settings.

Significant Symptom Relief for Treatment-Resistant Patients

The trial enrolled 60 adults who had not responded to standard treatments for major depression. These participants were divided into two groups: one receiving psilocybin and the other receiving a placebo. Both cohorts received standardized psychological support as part of the clinical protocol.

Those who received psilocybin showed significant improvements in their depression symptoms compared to the placebo group. According to the Nature Medicine report, the treatment demonstrated good tolerability, suggesting the intervention can be safely administered when paired with professional psychological oversight.

Testing the NHS Delivery Model

This study differs from previous research by taking place within a public healthcare system rather than a private clinic or an independent university-led trial. By utilizing the NHS in England, researchers tested whether psilocybin-assisted therapy could be integrated into the existing public health delivery model.

A core component of the approach is the combination of a pharmacological agent and structured mental health support.

Alternatives to Conventional Antidepressants

Scaling Psychedelic Therapy in Government Health

These results provide a basis for further research into how public health systems can scale psychedelic-assisted therapies.